drugset

drugset / Trial / NCT02944864

A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics

NCT02944864 ↗

Phase 1 Terminated 53 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

To study the pharmacokinetic characteristics of TQ-B3395 in the human body, recommend a reasonable regimen for subsequent research.

Timeline

Start: 2017-09-13
Primary completion: 2021-05-23
Completion: 2022-09-15

Outcome

Outcome not reported

Stopped: “Per sponsor request.”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TQ-B3395	Unknown	—	Oral

Indications